GLP-1 sales top $20B in 3Q25

Total quarterly sales for major branded GLP-1R agonists surpassed $20 billion for the first time in 3Q25, with Eli Lilly’s Mounjaro extending its lead as the top-selling therapy.

Eight GLP-1-based therapies sold by Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY) had combined 3Q25 sales of $20.3 billion — nearly double the combined sales of the same eight products in 4Q23. ...